Management of in-sent restenosis after carotid artery stenting in high-risk patients  by Zhou, Wei et al.
From the Peripheral Vascular Surgery Society
Management of in-sent restenosis after carotid
artery stenting in high-risk patients
Wei Zhou, MD, Peter H. Lin, MD, Ruth L. Bush, MD, Eric K. Peden, MD, Marlon A. Guerrero, MD,
Panagiotis Kougias, MD, and Alan B. Lumsden, MD, Houston, Tex
Background: Carotid artery stenting (CAS) has emerged as an acceptable treatment alternative in patients with carotid
bifurcation disease. Although early results of CAS have been promising, long-term clinical outcomes remain less certain.
We report herein the frequency, management, and clinical outcome of in-stent restenosis (ISR) after CAS at a single
academic institution.
Methods: Clinical records of 208 CAS procedures in 188 patients with carotid stenosis of 80% or greater, including 48
(26.5%) asymptomatic patients, during a 42-month period were analyzed. Follow-up serial carotid duplex ultrasound
scans were performed. Selective angiography and repeat intervention were performed when duplex ultrasound scans
showed 80% or greater ISR. Treatment outcomes of ISR interventions were analyzed.
Results: Over a median 17-month follow-up, 33 (15.9%) ISRs of 60% or greater were found, according to the Doppler
criteria. Among them, seven patients (3.4%) with a mean age of 68 years (range, 65-87 years) developed high-grade ISR
(>80%), and they all underwent further endovascular interventions. Six patients with high-grade ISR were asymptom-
atic, whereas one remaining patient presented with a transient ischemic attack. Five of seven ISRs occurred within 12
months of CAS, and two occurred at 18 months’ follow-up. Treatment indications for initial CAS in these seven patients
included recurrent stenosis after CEA (n  4), radiation-induced stenosis (n  1), and high-cardiac-risk criteria (n  2).
Treatment modalities for ISR included balloon angioplasty alone (n  1), cutting balloon angioplasty alone (n  4),
cutting balloon angioplasty with stent placement (n  1), and balloon angioplasty with stent placement (n  1).
Technical success was achieved in all patients, and no periprocedural complications occurred. Two patients with
post-CEA restenosis developed restenosis after ISR interventions, both of whom were successfully treated with cutting
balloon angioplasty at 6 and 8 months. The remaining five patients showed an absence of recurrent stenosis or symptoms
during a mean follow-up of 12 months (range, 3-37 months). By using the Kaplan-Meier analysis, the freedom from 80%
or greater ISR after CAS procedures at 12, 24, 36, and 42 months was 97%, 97%, 96%, and 94%, respectively.
Conclusions: Our study showed that ISR after CAS remains uncommon. Successful treatment of ISR can be achieved by
endovascular interventions, which incurred no instance of periprocedural complications in our series. Patients who
developed ISR after CEA were likely to develop restenosis after IRS intervention. Diligent ultrasound follow-up scans are
important after CAS, particularly in patients with post-CEA restenosis. ( J Vasc Surg 2006;43:305-12.)Since balloon angioplasty and stent placement in the
carotid artery was first introduced more than a decade ago,1
this treatment paradigm has become increasingly adapted
in the medical community. Despite an increased volume of
carotid artery stenting (CAS) being performed worldwide,
carotid endarterectomy (CEA) remains the standard treat-
ment in patients with carotid occlusive disease. As reported
in a recent consensus statement from the American Heart
Association, this minimally invasive procedure should be
offered to a limited group of high-risk patients. These
high-risk patients include those with severe cardiopulmo-
nary comorbidities, recurrent stenosis after endarterec-
tomy, prior neck irradiation, and inaccessible lesions above
the C2 level.2,3
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doi:10.1016/j.jvs.2005.10.040The short-term efficacy of CAS when compared with
CEA has been studied in several large prospective trials.
The Carotid and Vertebral Artery Transluminal Angio-
plasty Study, which evaluated patients with high-grade
carotid stenosis undergoing either CEA or balloon angio-
plasty, showed similar clinical outcomes between the two
treatment modalities during the 3 years of follow-up.4
Additionally, the SAPPHIRE trial confirmed that CASwith
a distal protection device performed similarly to the endar-
terectomy. Moreover, patients treated with CAS experi-
enced a significantly lower rate of perioperative myocardial
infarction in contrast to the CEA group.5,6 A study reported
by our group also revealed that CAS with routine use of a
cerebral protection device is a feasible and effective treat-
ment in high-risk patients with carotid occlusive disease.7
Despite the early promising results of these reports,
questions remain regarding the long-term durability of this
endovascular treatment modality.8-11 Reports suggesting a
low incidence of CAS-related in-stent restenosis (ISR) were
largely derived from studies with relatively small sample
sizes and short follow-up periods.8-13 The purposes of this
study were to examine the incidence of CAS-associated ISR
in our clinical experiences and to assess the durability of
endovascular intervention in the management of ISR.
305
JOURNAL OF VASCULAR SURGERY
February 2006306 Zhou et alMATERIALS AND METHODS
Hospital charts and clinical records were reviewed for all
patients who underwent CAS over a 42-month period end-
ing in May 2005. All CAS procedures were performed by
vascular surgeons at Baylor College of Medicine–affiliated
hospitals, including the Michael E. DeBakey VA Medical
Center and the Methodist Hospital. Carotid duplex scans
were performed before the stenting procedure, and high-
grade carotid stenosis was documented in all patients.
High-risk patients with symptomatic carotid stenosis 80%
or greater and asymptomatic carotid stenosis 80% or
greater were considered for the stenting protocol. Proce-
dural indications, techniques, and treatment outcomes were
analyzed.
Patient selection criteria. Eligibility for high-risk pa-
tients undergoing CAS was largely based on criteria estab-
lished at a recent consensus conference that included various
anatomic considerations, such as high carotid bifurcation
(higher than the C2 level), contralateral carotid occlusion,
presence of tracheostomy, history of ipsilateral neck irradi-
ation, prior radical neck dissection, or CEA.3 The high-risk
criteria also included patients with one or more medical
comorbidities, such as those myocardial infarction or stroke
in the previous 3 months. High-risk pulmonary dysfunc-
tion included patients with steroid-dependent chronic ob-
structive pulmonary disease or a measured forced expira-
tory volume in 1 second less than 30% of predicted or less
than 1 L/s. Finally, high-risk cardiac dysfunction included
those with a left ventricular ejection fraction less than 30%
and documented heart failure (stage III or IV of the New
York Heart Association classification).
Stenting technique. The antithrombotic protocol for
carotid stenting has been described previously. The patient
was given clopidogrel (75 mg/d) and aspirin (81 mg/d)
beginning 3 days before the intervention. After the stenting
procedure, clopidogrel was continued for 3 months, and
aspirin was continued for life. Before June 2002, all patients
undergoing carotid stenting received an intravenous (IV)
heparin bolus (100 U/kg) to achieve systemic anticoagu-
lation during the carotid intervention. After June 2002, the
intraoperative anticoagulation regimen was changed to an
IV bivalirudin bolus (0.75 mg/kg) followed by an infusion
rate of 2.5 mg · kg1 · h1. At the completion of the
carotid stenting, IV bivalirudin was discontinued.
All carotid stenting procedures were performed in the
operating room with routine use of embolization protec-
tion devices (EPD). A team consisting of two staff physi-
cians performed the carotid stenting procedure by using
either an endovascular operative suite (Siemens; Siemens
Medical Systems Inc, Iselin, NJ) or a mobile fluoroscopic
unit (OEC 9800; GE Medical Systems, Fairfield, CT). An
anesthesiologist was present to monitor the blood pressure
as recorded by an arterial line. Oximetry and continuous
electrocardiography were similarly monitored. The tech-
nique of stenting has been described previously.7 Briefly, a
7F, 90-cm carotid guiding sheath (Boston Scientific, Natick,
Mass) was placed in the distal common carotid artery(CCA) by tracking over the 0.035-inch stiff Glidewire or
Amplatz guidewire (Boston Scientific). The stiff wire was
routinely positioned in the external carotid artery to facili-
tate advancement of the guide sheath. The stiff guidewire
was next removed, and selective digital carotid angiogram
was performed via the sideport of the guiding sheath.
Biplanar intracranial injections were also performed to doc-
ument cerebral vasculature. A 0.018-inch guidewire system
with the EPD was then manipulated to cross the internal
carotid lesion. After the activation of the EPD, a coaxial
angioplasty balloon was used to predilate the carotid lesion
if necessary. Next, a self-expanding monorail carotid stent
(Wallstent [Boston Scientific] or Acculink [Guidant, Santa
Clara, Calif]) was deployed across the internal carotid ste-
nosis. Poststenting balloon angioplasty was performed with
either a 5- or 6-mm-diameter angioplasty balloon, depend-
ing on the appearance of the completion angiogram. Com-
pletion angiogram, including biplanar carotid and cerebral
views to document the vascular anatomy and to exclude
cerebral thromboembolism, was performed before the cap-
ture of the EPD. The shuttle sheath was subsequently
removed, and the groin puncture site was routinely closed
with a 6F femoral closure device (Perclose; Abbott Labo-
ratories, North Chicago, Ill).
Surveillance protocol. Patients were routinely kept in
the hospital overnight and discharged home on the follow-
ing day. Follow-up visits with carotid duplex ultrasound
scans were performed at 1, 6, and 12 months after the inter-
vention and each year thereafter. Patients who required
interventions for clinically significant restenosis after CAS
were evaluated with duplex ultrasound scans at 3-month
intervals. All duplex ultrasound scans were performed at
approved vascular laboratories accredited by the Intersoci-
ety Commission on Accreditation of Vascular Laboratories.
The surveillance studies were performed by seven experi-
enced ultrasonographers.
The velocity criteria used to evaluate carotid artery
stenosis were modified from the University of Washington
criteria and were validated in our laboratories. Briefly, peak
systolic velocity greater than 125 cm/s, end-diastolic ve-
locity less than 140 cm/s, and an internal carotid artery
ICA/CCA ratio less than 3.2 correlates with 50% to 59%
stenosis; ICA/CCA between 3.2 and 4 correlates with 60%
to 69% stenosis; ICA/CCA greater than 4 correlates with
70% to 79% stenosis; and end-diastolic velocity greater than
140 cm/s correlates with greater than 80% stenosis. Addi-
tionally, luminal reductions on grayscale images and color
flow disturbances were further evaluated. This is particu-
larly important for poststent surveillance. Clinically signifi-
cant stenosis was defined as luminal reduction of 80% or
higher. High-grade in-stent stenosis, identified by ultra-
sonography, was further verified by biplanar carotid an-
giography, and the stenosis was measured geometrically on
the basis of the North American Symptomatic Carotid
Endarterectomy Trial criteria. Carotid angioplasty and pos-
sible stenting were subsequently performed by following
the standard protocol upon confirmation of the lesions.
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sociated with restenosis after CAS were analyzed. For the
purposes of this analysis, we compared relevant clinical data
in patients with no ISR versus those with amoderate degree
of ISR (60%). Wilcoxon rank sum tests, 2 analyses, or
paired Student t tests were performed where appropriate.
Kaplan-Meier methods were also used to analyze the pa-
tency data. The procedural success rates were based on the
primary success of CAS. The test results were considered
significant at a P  .05. All statistical analyses were per-
formed with the StatView software program (SAS Institute,
Cary, NC).
RESULTS
Patient characteristics. A total of 208 CAS procedures
were performed in 188 patients, including 48 (26.5%) asymp-
tomatic patients, during the study period. They included
163 men and 25 women with a mean age of 69.3 years
(range, 55-87 years). Among them, 33 patients (15.9%)
developed moderate ISR of 60% or greater on post-CAS
duplex ultrasonography. Epidemiologic data, preproce-
dural risk factors, and presenting symptoms were similar
between patients without ISR and those withmoderate ISR
(Table I). When the indications for CAS were compared
between these two groups, a significantly higher propor-
tion of patients with ISR had post-CEA stenosis (58%)
when compared with those who did not have significant
ISR (11%; P  .03; Table I).
Clinical outcomes. Technical success was achieved in
204 (98%) of the 208 CAS procedures. Four procedures
were considered technical failures: three were due to the
severe tortuosity of the aortic arch, which precluded safe
advancement of the guiding catheter, and the fourth was
due to failure in traversing the carotid stenosis. Among the
204 successful CAS cases, the carotid artery stenosis de-
creased from 85%  12% (mean  SD) before the stent
placement to a poststenting mean residual stenosis of
10%  5%. Monorail Wallstents were used in 176 (86%)
CAS procedures, and Acculink stents were placed in the
remaining 28 (14%) carotid arteries. All stenting proce-
dures were performed by using an EPD, including the
PercuSurge Guardwire device (Medtronic, Santa Rosa,
Calif; n  22; 11%), the Filterwire system (Boston Scien-
tific; n 154; 75%), or an Accunet EPD (Guidant; n 28;
14%). The overall 30-day stroke and death rate was 2.4%
(n  5). This included one hemispheric stroke due to
immediate carotid stent thrombosis, which was successfully
treated with rheolytic thrombectomy. Three patients died
of myocardial infarction after discharge at 22 days, 6
months, and 10months, and one patient died of respiratory
failure 5 months later. There was no difference in the
overall complication rate between symptomatic and asymp-
tomatic patients (7.3% and 5.9%, respectively). Similarly,
no significant differences in overall stroke and death rates
were noted between the symptomatic and asymptomatic
groups (5.9% and 1.8%, respectively). The mean in-hospital
length of stay was 1.7  1.4 days. With Kaplan-Meier
analysis, the rates of freedom from 80% or greater ISR afterCAS procedures at 12, 24, 36, and 42 months were 97%,
97%, 96%, and 94%, respectively (Fig 1). The rates of
freedom from 60% or greater restenosis at 12, 24, 36, and
42 months were 97%, 95%, 92%, and 92%, respectively (Fig
2). Six patients had groin hematoma, including one patient
who required blood transfusion and one patient who de-
veloped a common femoral artery pseudoaneurysm. No
groin infection was observed in our series.
Follow-up and in-stent stenosis. During a median
follow-up of 17 months (range, 3-20 months), five patients
were lost to follow-up. Seven patients were found to have
80% or greater ISR that was confirmed by angiography
and subsequently treated with endovascular interventions.
They were six men and one woman with a mean age of
68 years (range, 65-87 years). No differences in ISR were
noted among different carotid stents or EPD devices. Sim-
ilarly, no difference in outcome was found when comparing
patients who received poststenting balloon angioplasty
Table I. Comparison of demographic characteristics,
clinical symptoms, comorbidities, and CAS indications
of patients without significant ISR and patients with
ISR 60% or greater
Variable
No
significant
ISR
Moderate
ISR
(60%)
P
value
Total no. patients 155 33
Age, y (mean  SD) 69  11 67  16 NS
Male sex 126 (81%) 27 (82%) NS
Asymptomatic carotid lesion 39 (25%) 9 (27%) NS
Symptomatic carotid lesion
Stroke 28 (18%) 8 (24%) NS
Transient ischemic attack 52 (34%) 11 (33%) NS
Amaurosis fugax 36 (23%) 5 (15%) NS
Comorbidities
Coronary artery disease 115 (74%) 23 (70%) NS
Congestive heart failure 33 (21%) 6 (18%) NS
History of myocardial
infarction 39 (25%) 9 (27%) NS
Smoking 113 (73%) 23 (70%) NS
Hypertension 121 (78%) 26 (79%) NS
Diabetes 53 (34%) 10 (30%) NS
Chronic obstructive
pulmonary disease 37 (24%) 8 (24%) NS
Hypercholesterolemia 59 (38%) 12 (36%) NS
Renal insufficiency
(creatinine 1.5 mg/dL) 20 (13%) 3 (9%) NS
CAS indications
High-risk cardiac
comorbidity 73 (47%) 18 (55%) NS
High-risk pulmonary
comorbidity 12 (8%) 4 (12%) NS
History of neck irradiation 9 (6%) 3 (9%) NS
Post-CEA stenosis 17 (11%) 19 (58%) .03
High carotid bifurcation 5 (3%) 1 (0.3%) NS
Status post radical neck
dissection 3 (2%) 1 (0.3%) NS
Cervical fusion 2 (1%) 0 (0%) NS
Tracheostomy 1 (1%) 0 (0%) NS
CAS, Carotid artery stenting; ISR, in-stent restenosis; NS, not significant;
CEA, carotid endarterectomy.with a 5- or 6-mm balloon catheter. Clinical characteristics
of e
of e
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in these patients are listed in Table III. Four of the seven
patients had initial stents placed for recurrent stenosis after
CEAs. One patient presented with a transient ischemic
attack, and the remaining six patients were asymptomatic.
All seven patients underwent endovascular interventions,
and the average time interval of reintervention from the
Fig 1. Kaplan-Meier analysis of freedom from 80% o
represent the number of patients at risk at the beginning
Fig 2. Kaplan-Meier analysis of freedom from 60% o
represent the number of patients at risk at the beginninginitial CAS procedure was 14 months (range, 3-20 months).With regard to endovascular treatment strategies, they in-
cluded percutaneous balloon angioplasty alone (n  1),
cutting balloon angioplasty (n  4), balloon angioplasty
with stent placement (n  1), and cutting balloon angio-
plasty (n  1; Table III). Technical successes, as defined by
resolution of the stenosis after treatment, were achieved in
all patients, and the mean carotid artery stenosis de-
ater restenosis. Numbers at the bottom of the figure
ach time period.
ater restenosis. Numbers at the bottom of the figure
ach time period.r grer grecreased from 88% to 16% after reintervention. No
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intervention. During a median follow-up period of 9
months after ISR intervention, two patients developed
recurrent stenosis, and additional interventions with a
cutting balloon angioplasty were successfully performed
at 6 and 8 months.
DISCUSSION
The efficacy of CEA has been demonstrated in numer-
ous clinical investigations, and CEA continues to be the
gold standard for patients with high-grade carotid steno-
sis.14,15 However, significant cardiopulmonary morbidities
and difficult surgical anatomies can potentially increase
procedure-related complications in a subset of patients who
undergo CEA. Therefore, carotid stenting is advocated as
an effective alternative to CEA for this subgroup of pa-
tients.3,16 Nonetheless, well-documented hemodynami-
cally significant ISR after carotid stenting has raised con-
cerns regarding the long-term durability of the procedure.
Our study and several others confirmed that the rate of
clinically significant ISR is relatively low.1,8,10-12,17,18 Fur-
thermore, our study identified higher incidences of ISR in
patients who had prior CEAs. This highlights that post-
CEA stenosis is associated with an increased risk of reste-
nosis after stenting and that endovascular intervention for
restenosis is safe and effective.
Several recent prospective clinical trials have docu-
Table II. Clinical characteristics of patients with
high-grade ISR (80%)
Variable Data
Total no. patients 7
Male sex 6 (86%)
Asymptomatic carotid lesion 6 (86%)
Symptomatic carotid lesion
Stroke 0 (0%)
Transient ischemic attack 1 (14%)
Amaurosis fugax 0 (0%)
Comorbidities
Coronary artery disease 5 (71%)
Congestive heart failure 0 (0%)
History of myocardial infarction 2 (29%)
Smoking 4 (57%)
Hypertension 5 (71%)
Diabetes 3 (43%)
Chronic obstructive pulmonary disease 2 (29%)
Hypercholesterolemia 3 (43%)
Renal insufficiency (creatinine 1.5 mg/dL) 0 (0%)
CAS indications
High-risk cardiac comorbidity 2 (29%)
High-risk pulmonary comorbidity 0 (0%)
History of neck irradiation 1 (14%)
Post-CEA stenosis 4 (57%)
High carotid bifurcation 0 (0%)
Status post radical neck dissection 0 (0%)
Cervical fusion 0 (0%)
Tracheostomy 0 (0%)
ISR, In-stent restenosis; CAS, carotid artery stenting; CEA, carotid endar-
terectomy.mented the efficacy of carotid stenting. As one of the earlyclinical investigations on percutaneous carotid interven-
tion, the Carotid and Vertebral Artery Transluminal Angio-
plasty Study evaluated patients with high-grade carotid
stenosis.4 The trial randomized 251 patients with high-
grade carotid stenosis to balloon angioplasty and 253 co-
hort patients to endarterectomy.4 The incidences of 30-day
and overall disabling stroke or death were similar between
the endovascular and surgical groups.4 One significant
finding from this study was markedly reduced operative
morbidity, such as cranial nerve palsy, in the endovascular
groups (0%) compared with the endarterectomy group
(8.7%). Similarly, the SAPPHIRE trial confirmed that ca-
rotid stenting with distal protection devices was not inferior
to endarterectomy for both asymptomatic patients with
80% or greater stenosis and symptomatic patients.5,6 We
recently reported our experiences of carotid stenting with
routine cerebral protection devices in high-risk patients.7
We achieved a 30-day stroke and death rate of 2.7% and an
overall complication rate of 6.9% and did not detect a
significant difference between the symptomatic and asymp-
tomatic patients. All stented vessels remained patent during
a mean follow-up of 15 months. These findings were
further confirmed by this series of 204 patients. Moreover,
several multicenter prospective trials are ongoing to evalu-
ate the efficacy of CAS. The Carotid Revascularization
Endarterectomy versus Stent Trial randomizes symptom-
atic patients who are at low surgical risk to either stenting or
endarterectomy.19,20 The trial is expected to enroll 2500
patients and to be completed by 2007. The Acculink for
Revascularization for Carotids in High Risk Patient Regis-
try trial is another ongoing study that is conducted in both
Europe and the United States; it involves 581 consecutive
patients in 3 single arms. The interim results have been
presented at the annual meetings of the Society of Inter-
ventional Radiology and the American College of Cardiol-
ogy, but the 1-year data of all three arms are not yet
available.
Although carotid percutaneous intervention is a safe
and effective alternative to CEA, hemodynamically signifi-
cant ISR (80%) after carotid stenting has raised concerns
regarding the long-term durability of carotid stenting (Ta-
ble IV).8,10-13 Setacci et al12 reported a 3.6% incidence of
high-grade restenosis (80%) during their follow-up of
more than 372 carotid stents. Similarly, Chakhtoura et al10
reported an 8% high-grade ISR rate during their 18-month
follow-up of 50 carotid stent procedures. Their slightly
higher ISR rate is likely reflected by the high percentage of
patients whose carotid stents were performed for postsur-
gical restenosis. The same group later reported a restenosis
rate of 5% and predicted a 5-year clinically significant ISR
rate of 6.4% by using life-table analysis and Kaplan-Meier
survival curves.8 Additionally, Willfort-Ehringer et al11 ob-
served a 3% high-grade ISR rate during their mean of 12
months’ follow-up of 303 Wallstents. Furthermore, they
prospectively evaluated 125 carotid stent procedures by
using ultrasonography and demonstrated that the diame-
ters of the self-expanding stents steadily increased over 2
years and that the neointimal thickness increased up to 12
remen
TA, c
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lated that the complex interaction between neointimal
proliferation and stent expansion might contribute to the
good mid-term outcome of carotid stenting.21 Our study,
likewise, demonstrated a 3.4% high-grade ISR rate during a
mean of 17 months’ follow-up among all patients who
underwent carotid stenting.However, the true incidence of
ISR in our series is likely to be higher because of a small
percentage of the patients lost to follow-up, particularly
patients who were referred from outside facilities. When
comparingmedical comorbidities and patient demographic
characteristics, there were no significant differences be-
tween the patients who developed ISR and those without
significant ISR, as demonstrated in Table I. However, our
analysis of the CAS indications revealed that post-CEA
stenosis was associated with an increased risk of poststent-
ing ISR (Table I). Similar findings were also recently re-
ported by Setacci et al,9 who noted a 3.6% ISR rate after
407 CAS procedures. These researchers found that post-
CEA restenosis was an independent predictive factor for the
development of ISR. One possible explanation for this
Table III. Treatment strategies and clinical outcome in p
Patient
no.
Initial CAS
indications
Presenting
ISR symptoms Treat
1 Post-CEA stenosis Asymptomatic PTA (5.5-mm
2 Cardiac morbidity Asymptomatic CB-PTA (6-mm
3 Neck irradiation Asymptomatic CB-PTA (5.5-m
and CAS (8-
4 Post-CEA stenosis TIA CB-PTA (5-mm
5 Cardiac morbidity Asymptomatic PTA (5-mm ba
CAS (8-mm
6 Post-CEA stenosis Asymptomatic CB-PTA (5.5-m
7 Post-CEA stenosis Asymptomatic CB-PTA (6-mm
ISR, In-stent restenosis; CAS, carotid artery stenting; CEA, carotid endarte
percutaneous transluminal angioplasty; TIA, transient ischemic attack.
Degrees of stenosis were calculated by using angiographic calibrated measu
Table IV. Published reports on endovascular intervention
Study
Total no.
patients PTA C
Chakhtoura (2001)10 4 (8%) 3 
Willfort-Ehringer (2002)11 9 (3%) 3 
Lal (2003)8 4 (4.1%) 3 
Chan (2003)27 1
Bendok (2003)26 3
Tamberella (2004)25 1
Setacci (2005)12 15 (3.6%) 3 
Levy (2005)13 6 (5%) 5 
Current study 7 (3.4%) 1
ISR, In-stent restenosis; PTA, percutaneous transluminal angioplasty; CB-Pphenomenon might be related to the aggressive intimalhyperplastic reaction in this patient cohort, whether the
method of carotid intervention was endarterectomy or
stent placement.
As demonstrated by our study and several other clinical
investigations, restenosis after carotid stenting is not un-
common, and postprocedural follow-up is essential in iden-
tifying patients with hemodynamically significant resteno-
sis. Duplex ultrasonography, a standard imaging tool for
carotid artery evaluation, is not as reliable for poststent
surveillance, largely because of a lack of well-established
ultrasound criteria and falsely increased velocities associated
with increased stiffness of the stented ICA. Ringer et al17
examined their ultrasound criteria for poststent surveillance
and concluded that strict flow velocity criteria for restenosis
after CAS were less reliable than changes in velocity over
time. Similarly, Lal et al22 compared postcarotid stenting
ultrasound velocity with angiographically measured resid-
ual in-stent stenosis and proposed a new criterion that
defined peak systolic velocity greater than 150 cm/s with
ICA/CCA greater than 2.16 as the best correlation with a
greater than 20% ISR. Our vascular laboratories, likewise,
ts with high-grade ISR
ISR %
before
treatment
ISR %
after
treatment Outcome
n) 80 20 Restenosis (80%) at 6 mo
treated with CB-PTA
oon) 90 20 Died of MI at 14 mo
alloon)
iameter)
80 10 No restenosis at 8 mo of
follow-up
oon) 98 30 No restenosis at 3 mo of
follow-up
) and
ter)
90 20 No restenosis at 12 mo of
follow-up
alloon) 90 5 No restenosis at 8 mo of
follow-up
oon) 85 10 Restenosis (80%) at 8 mo,
treated with CB-PTA
y; PTA, percutaneous transluminal angioplasty; CB-PTA, cutting balloon
ts.
ISR 80% or greater and follow-ups
ovascular treatment options
Recurrence (mo)TA Stenting Brachytherapy
1 0
6 2 (3 mo)
1 2 (12, 36 mo)
1 0
1 0
 NA
8 0
1 2 (14, 18 mo)
2 2 (6, 8 mo)
utting balloon percutaneous transluminal angioplasty; NA, not applicable.atien
ment
balloo
ball
m b
mm d
ball
lloon
diame
m b
ball
rectoms for
End
B-P
2
1
4 
0 
4have not established standard ultrasound velocity criteria to
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number of patients with ISR. Thus, we used a combination
of pre-existing validated velocity criteria in our laboratories
(end-diastolic velocity 140 cm/s and CCA/ICA 4
correlate with 80% stenosis) and diameter reduction on
grayscale, as well as significant color flow disturbance.More
importantly, all hemodynamically significant stenosis based
on sonographic evaluations is further confirmed by carotid
angiography before intervention.
Although the optimal treatment of high-grade ISR
after carotid stenting is still controversial, both surgical
intervention and endovascular therapy have been reported
as successful in the literature. Brown et al23 performed
bypasses on two patients with high-grade ISR with polytet-
rafluoroethylene grafts, whereas de Borst et al24 treated
four patients by using standard CEA and stent explanta-
tion. Nevertheless, surgical intervention is technically
demanding and potentially associated with substantial
procedural-related complications. Endovascular therapy,
conversely, provides the advantage of avoiding previously
stented arteries in high-risk patients. Several endovascular
techniques, including balloon angioplasty, cutting balloon
angioplasty, stenting, and, occasionally, brachytherapy,
have been described10-13,25-27 (Table IV). Chakhtoura et
al10 successfully treated four patients with angioplasty, with
or without stenting, and no complication was documented
during their mean 10 months of follow-up. Similar results
were reported by Setacci et al12 and Levy et al.13 Con-
versely, Willfort-Ehringer21 successfully treated nine pa-
tients with endovascular techniques, but two of their pa-
tients experienced major cerebral events 17 months later.
All our patients were successfully treated with endovascular
techniques, including one patient treated with balloon
angioplasty alone, four patients treated with cutting bal-
loons, and two patients with additional stent placements.
However, two patients required repeat cutting balloon
angioplasty 6 and 8 months later for recurrence of hemo-
dynamically significant stenosis.
In conclusion, restenosis after CAS is relatively uncom-
mon. Our study found that post-CEA stenosis is associated
with an increased risk of ISR after carotid stenting. Endo-
vascular intervention is an effective strategy in the treat-
ment of ISR, and repeat intervention may be necessary.
Furthermore, our study underscores that routine post-CAS
surveillance plays a fundamental role in identifying patients
with hemodynamically significant restenosis, and a prospec-
tive randomized trial is warranted to establish reliable post-
stenting surveillance criteria.
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